cascadian therapeutics  board of directors home  contact us about us product pipeline clinical trials research partnering investors news  events contact us about us overview management team board of directors partnerships careers contact us board of directors distinguished and insightful leadership provides strategic guidance   board of directors christopher s henney phd dsc robert w azelby mba gwen a fyfe md steven p james ted w love md scott d myers daniel k spiegelman mba christopher s henney phd dsc chairman and director cascadian therapeutics committee membership compensation committee corporate governance and nominating committee christopher s henney phd dsc has served as the chairman of our board of directors since september  and as a member of our board of directors since march  previously dr henney cofounded three major publicly held us biotechnology companies immunex icos and dendreon and held a seat on the board of directors and executive positions at each company from  to  dr henney was chairman and chief executive officer of dendreon corporation dr henney currently serves as a vicechairman of the board of directors of cyclacel pharmaceuticals a developmentstage biopharmaceuticals company as a member of the board of directors of anthera pharmaceuticals inc a biopharmaceutical company and as a member of the board of directors of prothena corporation a biotechnology company dr henney received a phd in experimental pathology from the university of birmingham england where he also obtained his dsc for contributions in the field of immunology in  dr henney was elected to the hall of fame of the association of international biotechnology ceos dr henney is a former professor of immunology and microbiology and has held faculty positions at johns hopkins university the university of washington and the fred hutchinson cancer research center return to top  robert w azelby mba director cascadian therapeutics committee membership corporate governance and nominating committee robert w azelby mba has been a member of our board of directors since april  since november  mr azelby has served as the executive vice president chief commercial officer at juno therapeutics inc a biotechnology company prior to joining juno mr azelby was vice president and general manager oncology at amgen inc from june  to october  from october  to september  he served as amgens vice president amgen oncology sales prior to that he served in various positions at amgen including vice president commercial effectiveness unit and general manager of amgen netherlands mr azelby received his ba in economics and religious studies from the university of virginia and mba from harvard business school return to top  gwen a fyfe md director gwen a fyfe md has been a member of our board of directors since january  since  dr fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies and has been an invited member of institute of medicine panels national cancer institute working groups and grant committees and american society of clinical oncologists oversight committees from  to  dr fyfe held various positions with genentech inc now a member of the roche group including vice president oncology development vice president avastin® franchise team as well as the honorary title of senior staff scientist dr fyfe played an important role in the development of genentechs approved oncology agents including rituxan® herceptin® avastin® and tarceva® dr fyfe sat on the development oversight committee for all of genentechs products and participated in the research review committee that moved products from research into clinical development currently dr fyfe serves on the boards of array biopharma inc and infinity pharmaceuticals inc dr fyfe is a graduate of washington university school of medicine and a board certified pediatric oncologist return to top  steven p james director cascadian therapeutics committee membership audit committee compensation committee steven p james has been a member of our board of directors since february  mr james served as president and chief executive officer of labrys biologics inc from december  until its acquisition by teva pharmaceuticals in july  he was president and chief executive officer of kai pharmaceuticals inc from october  until its acquisition by amgen in july  he was senior vice president commercial operations at exelixis inc from  until  previously he held senior business roles at sunesis pharmaceuticals inc and isis pharmaceuticals inc he began his career in new product planning at eli lilly and company mr james is also a member of the board of directors of ocera therapeutics inc and chrono therapeutics mr james earned a bachelor of arts degree in biology from brown university and a masters in management degree from the kellogg graduate school of management at northwestern university return to top  ted w love md director cascadian therapeutics committee membership audit committee compensation committee ted w love md has been a member of our board of directors since september  since june  dr love has served as chief executive officer of global blood therapeutics inc from february  to august  dr love served as executive vice president and head of research and development and technical operations at onyx pharmaceuticals inc from  to january  dr love served as chairman and chief executive officer of nuvelo inc dr love joined nuvelo from theravance inc where he served as senior vice president of development from  to  previously he spent six years at genentech inc where he held a number of senior management positions in medical affairs and product development and served as chairman of genentechs product development committee dr love also serves as a member of the boards of directors of biopharmaceutical companies amicus therapeutics inc and kalobios pharmaceuticals inc until april  he served on the california independent citizens oversight committee dr love earned his bachelor of science in molecular biology from haverford college and his md from yale medical school return to top  scott d myers director president and ceo cascadian therapeutics inc scott d myers has served as our president chief executive officer and been a member of our board of directors since april  prior to joining cascadian therapeutics mr myers served as the chief executive officer of aerocrine ab life sciences company from september  until it was acquired by circassia pharmaceuticals plc in july  from january  to august  mr myers served as a vice president of ucb sa a biopharmaceutical company in this role myers oversaw commercial operations and medical affairs for  countries in the eu from december  to january  mr myers served as the chief commercial officer for dov pharmaceutical a development stage pharmaceutical company and from  to  mr myers held several senior positions at johnson  johnson including senior vice president and general manager additionally from april  to april  mr myers served as a member of the board of directors of orexo ab a pharmaceutical company and is currently an industry advisor for eqt an investment fund mr myers received his bachelor of arts degree in biology from northwestern university and mba from the graduate school of business from the university of chicago return to top  daniel k spiegelman mba director cascadian therapeutics committee membership audit committee corporate governance and nominating committee daniel k spiegelman mba has been a member of our board of directors since june  mr spiegelman was appointed executive vice present and chief financial officer of biomarin pharmaceuticals in may  from october  until may  mr spiegelman served as a consultant to provide strategic financial support to a portfolio of public and private life sciences companies from  to  mr spiegelman was employed at cv therapeutics inc a biopharmaceutical company most recently as senior vice president and chief financial officer from  to  mr spiegelman was an employee at genentech inc a biotechnology company serving most recently as treasurer mr spiegelman also serves as a member of the board of directors of relypsa inc a developmentstage biopharmaceutical company mr spiegelman received his ba and mba from stanford university return to top  about us overview management team board of directors partnerships careers contact us product pipeline pipeline ont checkpoint kinase  antibodyimmunotherapy clinical data and scientific presentations clinical trials research checkpoint kinase  antibodyimmunotherapy partnerships news  events press releases events  presentations email alerts investors overview stock information stock info historical lookup analyst coverage financial information recent financials quarterly results annual reports sec filings annual reports  proxy corporate governance email alerts investor contact  site map  cascadian therapeutics legal notice site map  legal notice  cascadian therapeutics christopher s henney  former interim chief executive officer at cascadian therapeutics inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink christopher s henney former interim chief executive officer at cascadian therapeutics inc overview in the news relationships paths education career history boards  committees nonprofit donations  grants public holdings christopher s henney former interim chief executive officer at cascadian therapeutics inc overview age  born  notable companies cascadian therapeutics inc dendreon corp icos corporation board seats  number of relationships this person is connected to  people in the news see more globenewswire march   cascadian therapeutics announces changes to board of directors globenewswire february   anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results globenewswire april   anthera pharmaceuticals appoints brent furse to board of directors globenewswire march   oncothyreon appoints scott d myers chief executive officer globenewswire march   oncothyreon reports full year and fourth quarter  financial results  provides corporate update see full news coverage and complete stories with relsci professional create your news feed see more relationships see details daniel k spiegelman executive vice president  chief financial officer at biomarin pharmaceutical inc scott d myers president chief executive officer  director at cascadian therapeutics inc bogdan dziurzynski chair at regulatory affairs professionals society spiro rombotis president  chief executive officer at cyclacel pharmaceuticals inc paul f truex executive chairman at anthera pharmaceuticals inc david l urdal former director executive vice president  chief scientific officer at dendreon corp gene g kinney director president  chief executive officer at prothena corp plc paul mcbarron chief operating officer  secretary at cyclacel pharmaceuticals inc john craig thompson president  chief executive officer at anthera pharmaceuticals inc douglas e williams founding president  chief executive officer at codiak biosciences inc see  more listings with relsci professional start my free trial ➤ see  more paths to christopher s henney christopher s henney you connections via relationship science christopher s henney sync your contacts to see how you can connect with christopher s henney start my free trial ➤ see more educational background dsc in immunology  the university of birmingham birmingham has been challenging and developing great minds for more than a century characterised by a tradition of innovation research at the university has broken new ground pushed forward the boundaries of knowledge and made an impact on people’s lives we continue this tradition today and have ambitions for a future that will embed our work and recognition of the birmingham name on the international stage universities are never complete they develop as new challenges and opportunities occur at birmingham we innovate we push the frontiers of understanding we ask new research questions we turn theory through experiment into practice – because that’s what great universities do career history interim chief executive officer    cascadian therapeutics inc cascadian therapeutics inc is a clinicalstage biopharmaceutical company engages in the development of therapeutic products for the treatment of cancer its lead product candidate ont is an orally active and selective smallmolecule her inhibitor it also develops preclinical product candidates in oncology using chk kinase inhibitor and protocell technology the company was founded on september   and is headquartered in seattle wa cofounder    dendreon corp dendreon corp discovers develops and commercializes novel products for the treatment of cancer the company applies its expertise in antigen identification engineering and cell processing to produce active cellular immunotherapy aci product candidates designed to stimulate an immune response in a variety of tumor types it is an exploring the application of additional aci product candidates and small molecules for the potential treatment of a variety of cancers dendreon was founded by christopher s henney edgar g engleman and samuel strober in  and is headquartered in seattle wa cofounder    icos corporation icos corp manufactures medications to treat inflammation and other serious diseases it focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia hypertension pulmonary arterial hypertension cancer and inflammatory diseases the company was founded in  by christopher henney and george rathman and is headquartered in bothell wa cofounder    immunex corp immunex corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation professor immunology  microbiology prior the johns hopkins university the johns hopkins university opened in  with the inauguration of its first president daniel coit gilman what are we aiming at gilman asked in his installation address the encouragement of research  and the advancement of individual scholars who by their excellence will advance the sciences they pursue and the society where they dwell the mission laid out by gilman remains the universitys mission today summed up in a simple but powerful restatement of gilmans own words knowledge for the world what gilman created was a research university dedicated to advancing both students knowledge and the state of human knowledge through research and scholarship gilman believed that teaching and research are interdependent that success in one depends on success in the other a modern university he believed must do both well the realization of gilmans philosophy at johns hopkins and at other institutions that later attracted johns hopkinstrained scholars revolutionized higher education in america leading to the research university system as it exists today after more than  years johns hopkins remains a world leader in both teaching and research eminent professors mentor top students in the arts and music the humanities the social and natural sciences engineering international studies education business and the health professions those same faculty members and their research colleagues at the universitys applied physics laboratory have each year since  won johns hopkins more federal research and development funding than any other university the university has nine academic divisions and campuses throughout the baltimorewashington area the krieger school of arts and sciences the whiting school of engineering the school of education and the carey business school are based at the homewood campus in northern baltimore the schools of medicine public health and nursing share a campus in east baltimore with the johns hopkins hospital the peabody institute a leading professional school of music is located on mount vernon place in downtown baltimore the paul h nitze school of advanced international studies is located in washingtons dupont circle area the applied physics laboratory is a division of the university coequal to the nine schools but with a nonacademic researchbased mission apl located between baltimore and washington supports national security and also pursues space science exploration of the solar system and other civilian research and development johns hopkins also has a campus near rockville in montgomery county md and has academic facilities in nanjing china and in bologna italy it maintains a network of continuing education facilities throughout the baltimorewashington region including centers in downtown baltimore in downtown washington and in columbia when considered in partnership with its sister institution the johns hopkins hospital and health system the university is marylands largest employer and contributes more than  billion a year to the states economy professor prior fred hutchinson cancer research center fred hutchinson cancer research center provides research and testing services the company was founded in  and is headquartered in seattle wa boards  committees corporate boards ▾ independent director   current prothena corp plc prothena corp plc is a clinical stage biotechnology company which engages in the discovery development and commercialization of novel antibodies its antibodybased product candidates target a number of potential indications including al amyloidosis neod parkinsons disease and related synucleinopathies prx inflammatory diseases including psoriasis psoriatic arthritis prx and attr amyloidosis prx the company was founded on december   and is headquartered in dun laoghaire ireland vice chairman   current cyclacel pharmaceuticals inc cyclacel pharmaceuticals inc engages in the discovery development and commercialization of novel mechanismtargeted drugs to treat cancer and other serious disorders its lead candidate sapacitabine oral nucleoside analogue prodrug that acts through a novel mechanism it also develops seliciclib and cycsecond generation cdk inhibitor the company was founded by ronald j berenson david philip lane and david glover on august   and is headquartered in berkeley heights nj member board of directors   current anthera pharmaceuticals inc anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca chairman board of directors   current cascadian therapeutics inc cascadian therapeutics inc is a clinicalstage biopharmaceutical company engages in the development of therapeutic products for the treatment of cancer its lead product candidate ont is an orally active and selective smallmolecule her inhibitor it also develops preclinical product candidates in oncology using chk kinase inhibitor and protocell technology the company was founded on september   and is headquartered in seattle wa chairman of the board    mymetics corp mymetics corp engages in the provision of research and development it focuses in the prevention and treatment of the aids virus and malaria the company develops unique vaccines that focus on the mucosal layer as a first line of defense against viruses entering the blood stream and the development of virosomes as a new vaccine delivery platform mymetics was founded in july  and is headquartered in epalinges switzerland chairman    allostera pharma inc allostera pharma inc is a biopharmaceutical company that has developed an entirely new class of drugs called allosteramers™ allosteramers™ have three main properties  they are “allosteric” meaning they do not bind to the same site as traditional drugs potentially providing better safety efficacy and an entirely new set of patentable intellectual properties  they can have predictable and consistent drug properties and  they are designed to be orally availableusing its module x technology platform allostera has developed a pipeline of seven novel allosteramers™ against different targets primarily focused on inflammation and autoimmunity including apg a drug inhibiting the il receptor one of the most important targets in the autoimmune disease field apg has demonstrated oral activity in animal models of autoimmune diseases director    sarepta therapeutics inc sarepta therapeutics inc is a biopharmaceutical company which is engaged in the discovery and development of unique rnatargeted therapeutics for the treatment of rare infectious and other diseases it focuses on the development of its potentially diseasemodifying dmd drug candidates the company was founded on july   and is headquartered in cambridge ma chairman   prior xcyte therapies inc chairman    biomira inc biomira inc engages in the research and development of therapeutic products for the treatment of cancer the company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy director   prior oncogenex pharmaceuticals inc oncogenex pharmaceuticals inc is a biopharmaceutical company which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients its product include custirsen apatorsen and ogx the company was founded by martin e gleave and scott daniel cormack in october  and is headquartered in bothell wa director   prior biotechne corp biotechne corp engages in the development manufacture and sale of biotechnology products and clinical diagnostic controls it operates through three segments includebiotechnology clinical controls and protein platforms the biotechnology segment is a suppliers of specialized proteins such as cytokines growth factors immunoassays antibodies and related reagents to the biotechnology research community the clinical controls segment develops and manufactures controls and calibrators for instruments in the global clinical market the protein platforms segment develops manufactures and sells tools to make protein analysis simpler more quantitative and reproduceable the company was founded on july   and is headquartered in minneapolis mn executive chairman    dendreon corp dendreon corp discovers develops and commercializes novel products for the treatment of cancer the company applies its expertise in antigen identification engineering and cell processing to produce active cellular immunotherapy aci product candidates designed to stimulate an immune response in a variety of tumor types it is an exploring the application of additional aci product candidates and small molecules for the potential treatment of a variety of cancers dendreon was founded by christopher s henney edgar g engleman and samuel strober in  and is headquartered in seattle wa chairman prior sgx pharmaceuticals inc sgx pharmaceuticals inc researches and develops drugs and other pharmaceutical products the companys product pipeline includes drug candidates from its drug discovery platform which uses xray crystallography and complementary biophysical and biochemical methods combined with medicinal and computational chemistry the company was incorporated in june   and is headquartered in san diego ca nonprofit donations  grants     the american association of immunologists inc the american association of immunologists is an association of professionally trained scientists from all over the world dedicated to advancing the knowledge of immunology and its related disciplines fostering the interchange of ideas and information among investigators and addressing the potential integration of immunologic principles into clinical practice the american association of immunologists serves its members by providing a center for the dissemination of information relevant to the field and its practices such as educational and professional opportunities scientific meetings membershipderived issues and opinions and important social and political issues aai owns and publishes the journal of immunology—the largest and most highly cited journal in the field public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations christopher s henney is affiliated with cascadian therapeutics inc dendreon corp icos corporation immunex corp the johns hopkins university fred hutchinson cancer research center prothena corp plc cyclacel pharmaceuticals inc anthera pharmaceuticals inc cascadian therapeutics inc mymetics corp allostera pharma inc sarepta therapeutics inc xcyte therapies inc biomira inc oncogenex pharmaceuticals inc biotechne corp dendreon corp sgx pharmaceuticals inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ henney christopher s  the wall street transcript christopher s henney christopher s henney joined dendreon corporation as chief executive officer in may  in  dr henney cofounded icos corporation where from  to  he served as executive vice president scientific director and director in  dr henney cofounded immunex corporation where from  to  he held various positions including director vice chairman and scientific director prior to founding immunex dr henney was an academic immunologist serving as professor at johns hopkins university and then the university of washington where he also headed the immunology program at the fred hutchinson cancer research center dr henney received a bsc with honors a phd in experimental pathology and a dsc for his contributions to immunology from the university of birmingham england related interviewschristopher henney  dendreon corporation dndnjune  christopher henney  dendreon corporation dndnmay  christopher henney  dendreon corporation dndnoctober  christopher henney  dendreon corporation dndnoctober   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google christopher s henney phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in christopher s henney phd board member at anthera pharmaceuticals inc view full profile are you christopher s henney phd claim your profile   sign up for equilar atlas and view christopher s henney phds full profile with equilar atlas you can identify corporate executives in christopher s henney phds network and community follow changes in christopher s henney phds employment and moneyinmotion connect with christopher s henney phd through your network of contacts christopher s henney phds executive work history current board member prothena corporation plc board member anthera pharmaceuticals inc past to view christopher s henney phds complete executive work history sign up now education phd university of birmingham doctorate university of birmingham age      christopher s henney phds biography christopher s henney phd has served as the chairman of our board of directors since september  and as a member of our board of directors since march  dr henney is chair of our corporate governance and nominating committee and a member of our compensation committee dr henney also served as our interim president and chief executive officer from january  to april  from  to  dr henney was chairman and chief executive officer of dendreon corporation a publiclytraded biotechnology company that he cofounded and from  to  continued as executive chairman dr henney was also a cofounder of immunex corpor  read more christopher s henney phd has served as the chairman of our board of directors since september  and as a member of our board of directors since march  dr henney is chair of our corporate governance and nominating committee and a member of our compensation committee dr henney also served as our interim president and chief executive officer from january  to april  from  to  dr henney was chairman and chief executive officer of dendreon corporation a publiclytraded biotechnology company that he cofounded and from  to  continued as executive chairman dr henney was also a cofounder of immunex corporation and icos corporation both publiclytraded biotechnology companies our corporate governance and nominating committee believes that dr henneys qualifications for membership on the board of directors include his roles as cofounder of dendreon immunex and icos as well as his membership on the boards of directors of several developmentstage biotechnology companies through his experience in working with biotechnology companies from founding until commercialization of their product candidates dr henney provides our board of directors with significant insights into the strategic operational and clinical development aspects of the company dr henney currently serves as vicechairman of the board of directors of cyclacel pharmaceuticals inc a developmentstage biopharmaceuticals company as a member of the board of directors of anthera pharmaceuticals inc a biopharmaceutical company and as a member of the board of directors of prothena corporation plc a biotechnology company dr henney received a phd in experimental pathology from the university of birmingham england where he also obtained his dsc for contributions in the field of immunology in  he received the honorary degree of doctor of the university from his alma mater for contributions to the biotechnology industry and in  was elected to the hall of fame of the association of international biotechnology ceos dr henney is a former professor of immunology and microbiology and has held faculty positions at johns hopkins university the university of washington and the fred hutchinson cancer research center source cascadian therapeutics inc on    sign up for equilar atlas and view christopher s henney phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like christopher s henney phd more specifically youll be able to identify corporate executives in christopher s henney phds network and community follow changes in christopher s henney phds employment and moneyinmotion connect with christopher s henney phd through your network of conections view full profile   search for over  executive profiles bio example christopher s henney phd christopher s henney phds connections  sign up now to view christopher s henney phds  connections » douglas g watson former chairman of the board orasure technologies inc michael d casey lead independent director celgene corporation louis c bock board member orexigen therapeutics inc david c uprichard former chief executive officer dimensional pharmaceuticals inc william r shanahan senior vice president and chief medical officer anthera pharmaceuticals inc james i healy former board member ascendis pharma as debra odink former advisor anthera pharmaceuticals inc monica tsang former vice president research biotechne corporation stephen lau former vp corp  business dev anthera pharmaceuticals inc robert w azelby executive vice president and chief commercial officer juno therapeutics inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla david j oconnor president and ceo the madison square garden company claiborne p deming chairman of the board murphy oil corporation × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   christopher s henney cascadian therapeutics inc chairman  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   christopher s henney chairman cascadian therapeutics inc realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for christopher s henney at cascadian therapeutics inc christopher s henney works as chairman  acting in a executive management role  cascadian therapeutics inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more executive management leads or mediamarketing prospecting automation start a free trial now recent related news  definitive proxy statement  history of grants under the  eip the table below shows as to each of our executive officers named in the summary compensation table and the other identified groups below the aggregate number of awards granted to such person or group under the  eip during the last competed fiscal year christopher henney former interim chief executive officer and president and current director the following table sets forth information as of december   with respect to compensation plans under which shares of our common stock may be issued the table does not include information with respect to shares we are proposing to add to the  eip  people in this article christopher s henney  gary christianson  scott d myers  scott peterson  preliminary proxy statement  history of grants under the  eip the table below shows as to each of our executive officers named in the summary compensation table and the other identified groups below the aggregate number of awards granted to such person or group under the  eip during the last competed fiscal year christopher henney former interim chief executive officer and president and current director the following table sets forth information as of december   with respect to compensation plans under which shares of our common stock may be issued the table does not include information with respect to shares we are proposing to add to the  eip  people in this article christopher s henney  gary christianson  scott d myers  scott peterson learn more about christopher s henney and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about christopher s henney and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved insider trading  henney christopher s  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  henney christopher s select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing salea  pm prothena corp plc prta henney christopher sdirector    direct view sale  pm prothena corp plc prta henney christopher sdirector    direct view sale  pm prothena corp plc prta henney christopher sdirector    direct view sale  pm prothena corp plc prta henney christopher sdirector    direct view a indicate amendment filing stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na anthera pharmaceuticals inc anth henney christopher sdirector   direct view exercise  pm nana prothena corp plc prta henney christopher sdirector   direct view exercise  pm na prothena corp plc prta henney christopher sdirector   direct view option award  pm nana cascadian therapeutics inc casc henney christopher sinterim ceo and presidentdirector   direct view option award  pm  cyclacel pharmaceuticals inc cycc henney christopher sdirector   direct view option award  pm na prothena corp plc prta henney christopher sdirector   direct view option award  pm na anthera pharmaceuticals inc anth henney christopher sdirector   direct view option award  pm na oncothyreon inc onty henney christopher sinterim ceo and presidentdirector   direct view exercise  pm nana prothena corp plc prta henney christopher sdirector   direct view exercise  pm na prothena corp plc prta henney christopher sdirector   direct view exercise  pm nana prothena corp plc prta henney christopher sdirector   direct view exercise  pm na prothena corp plc prta henney christopher sdirector   direct view option award  pm nana oncothyreon inc onty henney christopher sdirector   direct view exercise  pm nana prothena corp plc prta henney christopher sdirector   direct view exercise  pm na prothena corp plc prta henney christopher sdirector   direct view exercise  pm nana oncothyreon inc onty henney christopher sdirector   direct view tax withholding  pm nana oncothyreon inc onty henney christopher sdirector   direct view option award  pm nana oncothyreon inc onty henney christopher sdirector   direct view exercise  pm nana oncothyreon inc onty henney christopher sdirector   direct view option award  pm  cyclacel pharmaceuticals inc cycc henney christopher sdirector   direct view option award  pm na prothena corp plc prta henney christopher sdirector   direct view option award  pm na anthera pharmaceuticals inc anth henney christopher sdirector   direct view   secformcom all rights reserved archives        sun  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  christopher s henney  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors christopher s henney check out list of companies and businesses related to christopher s henney find out christopher s henney address and contact details view other people related to christopher s henney  coworkers colleagues companions etc address  first avenue seattle  wa companies related to christopher s henney cikcompany namepositioncompany addressbiotechne corpdirector  mckinley place ne minneapolis dendreon corpchairman of the board  union street suite  seattle cyclacel pharmaceuticals incdirector  connell drive suite  berkeley heights anthera pharmaceuticals inc  industrial boulevard suite b hayward cascadian therapeutics incdirector  fourth avenue suite  seattle prothena corp plcdirector adelphi plaza upper georges street dun laoghaire co dublin a t christopher s henney on the web persons related to christopher s henney  biotechne corpnamepositioncityrobert v baumgartnerdirector minneapolisrobert v baumgartnerdirector robert v baumgartnerdirector minneapolisj fernando bazanchief technical officer minneapolischarles a dinarellodirector bouldern david eansorsvp  biotech east rutherfordn david eansorsvp  novus biologicals littletonbrenda s furlowsvp  general counsel madisonbrenda s furlowsvp  general counsel minneapolisrobert m gavinsenior vp protein platforms minneapoliskevin s gouldsvp clinical controls newbury parkchristopher s henneydirector seattlechristopher s henneydirector g a herbertdirector maitlandg a herbertdirector edgewaterjohn l higginsdirector palo altojohn l higginsdirector la jollajohn l higginsdirector san diegojohn l higginsdirector la jollajames hippelchief financial officer minneapoliskaren a holbrookdirector columbuskaren a holbrookdirector karen a holbrookdirector minneapoliskaren a holbrookdirector longboat keycharles r kummethchief executive officer schaumburgcharles r kummethchief executive officer minneapolisroger c lucasdirector north oaksroger c lucasdirector north oaksroger c lucasdirector north oaksgregory j melsencfo minneapolisgregory j melsenvp finance and cfo bloomingtonroeland nussedirector palo altohoward v oconnelldirector scottsdalehoward v oconnelldirector falcon heightsthomas e olandceo president minneapoliskevin j reagansenior vp  biotech minneapoliskevin j reagansenior vp  biotech minneapolisrandolph c steerdirector birminghamrandolph c steerdirector minneapolismonica tsangvp of research minneapolismarcel veronneausvp  clinical controls marcel veronneauvp clinical controls minneapolismarcel veronneausvp  clinical controls minneapolisjames a weatherbeechief scientific officer minneapolisharold j wiensdirector harold j wiensdirector minneapolispersons related to christopher s henney  dendreon corpnamepositioncityw thomas amickpres  chief executive officer seattlesusan b bayhdirector seattlesusan b bayhboard of director seattlesusan b bayhdirector seattlesusan b bayhdirector seattlehans edgar bishopchief operating officer seattlerichard b brewerdirector seattlerichard b brewerdirector santa cruzrichard b brewerdirector seattlekaren brophyvp human resources seattlemichelle burriscfo svp of fin  treasure seattlegerardo canetdirector seattlegerardo canetdirector seattlegerardo canetdirector bedford cornersgerardo canetdirector seattlegerardo canetdirector seattlegerardo canetdirector seattleian t clarkboard of director seattlegreg coxvp finance seattlegreg coxvp finance seattlegreg coxseattlegreg coxvp finance seattlegreg coxevp cfo  treasurer seattlerobert crottyevp general counsel seattlechristine mikail cvijicevp corp dev gen counsel seattlechristine mikail cvijicevp corp dev gen cnslscrtry seattlejoseph i depintoevp global commercial ops seattlejoseph i depintoevp global commercial ops seattlebogdan dziurzynskidirector cardinalbogdan dziurzynskidirector cardinalbogdan dziurzynskidirector seattlebogdan dziurzynskidirector seattlebogdan dziurzynskidirector seattlebogdan dziurzynskiodirector seattlebogdan dziurzynskiodirector seattledennis m fentondirector seattledennis m fentondirector seattlemark w frohlichsee general remarks seattlemark w frohlichsee general remarks seattlemark w frohlichsee remarks seattlemark w frohlichevp rd and cmo seattlemitchell goldceo mitchell goldpresident  chief executive of seattlemitchell goldpresident  ceo seattlemitchell goldpresident  ceo seattlemitchell goldpresident  ceo seattlemitchell goldpresident  chief executive of seattlemitchell golddirector seattlemitchell golddirector seattlepedro p granadilloboard of director seattlepedro p granadilloseattlepedro p granadillodirector seattlepedro p granadillodirector seattlerichard f hamm jrsvp gen counsel secretary seattlerichard f hamm jrevp general counsel secretary seattlerichard f hamm jrsvp general counsel secretary seattlechristopher s henneychairman of the board seattlechristopher s henneychairman of board of directors christopher s henneychaiman of the bod seattlerobert hershbergsr vp  chief medical officer seattlerobert hershbergchief medical officer seattlem blake ingledirector seattlem blake ingledirector seattlewilliam jenkinsonchief marketing officer seattlejohn johnsondirector seattlejohn johnsonchief executive officer seattlejohn johnsonpres  chief executive officer seattleruth kunathdirector seattleruth kunathdirector seattleruth kunathdirector seattlegregory t mayesevp human resources seattlewilliam monteithevp technical operations seattlejohn e osbornevp general counsel seattlejohn e osbornevp general counsel seattlesilvio pachecosvp sales and marketing seattlegrant pickeringsr vp operations seattlerobert s poultonevp technical operations seattlerobert s poultonevp technical operations seattlerichard j ranieriseattlerichard j ranierisvp human resources seattlerichard j ranierievp human resources seattlerichard j ranierievp human resources seattlerichard j ranierievp human resources seattlelindsay roccoevp corporate communications seattleandrew seth sandlerevp chief medical officer seattlegregory t schiffmancfo evp of finance  treasure seattlegregory t schiffmanevp seattlegregory t schiffmancfo svp of finance  treasure seattlegregory t schiffmancfo evp of finance  treasure seattlemartin a simonetisvp finance martin a simonetisr vp of fin cfo  treasurer seattlemartin a simonettisr vp of fin cfo  treasurer seattleburton e sobel colchesterdavid c stumpdirector seattledavid c stumpdirector seattledavid c stumpdirector seattleharris timothydirector solano beachdavid urdalpresident david urdalsvp chief scientific officer seattledavid urdalsvp chief scientific officer seattledavid urdaldirector seattledavid urdalsvp chief scientific officer seattledavid urdaldirector seattlegeorge p vlasuk carlsbaddouglas g watsondirector far hillsdouglas g watsondirector seattledouglas g watsondirector seattledouglas g watsondirector far hillsdouglas g watsondirector seattlepersons related to christopher s henney  cyclacel pharmaceuticals incnamepositioncityalta california management partners lpsan franciscoalta california partners lpsan franciscoalta embarcadero partners ii llcsan franciscoalta embarcadero partners llcsan franciscopartners altasan franciscoarch management partners ii lp owner chicagoarch management partners ii lp owner chicagoarch v entrepreneurs fund lpchicagoarch v entrepreneurs fund lpchicagoarch v entrepreneurs fund lp owner chicagoarch venture corpchicagoarch venture corpchicagoarch venture fund ii lp owner chicagoarch venture fund ii lp owner chicagoarch venture fund iii l p owner chicagoarch venture fund v lp owner chicagoarch venture fund v lp owner chicagoarch venture partners llc owner chicagoarch venture partners lpchicagoarch venture partners lpchicagoarch venture partners v lp owner chicagonicholas g bacopoulosdirector berkeley heightsnicholas g bacopoulosdirector berkeley heightsjohn michael middlecott banhamdirector short hillsjohn michael middlecott banhamdirector berkeley heightsjohn michael middlecott banhamdirector berkeley heightssam l barkerdirector the woodlandssam l barkerberkeley heightsronald j berensonpresident  ceo seattleronald j berensonpresident  ceo seattleronald j berensonpresident  ceo seattleronald j berensonpresident and ceo seattlejoanna s blackseattlejoanna s blackgeneral counsel vp  sec seattlejoanna s blackvp and general counsel secret seattlemark l bonyhadiseattlemark l bonyhadivp  research seattlemark l bonyhadivice president research seattleclinton bybeechicagoclinton bybee owner chicagoclinton bybee owner chicagojudy chiaovp clin dev  reg aff short hillsjudy chiaovp clin dev  reg aff berkeley heightsjudy chiaovp clin dev  reg aff berkeley heightsjudy chiaovp clin dev  reg aff berkeley heightsjudy chiaovp clin dev  reg aff berkeley heightsjudy chiaovp clin dev  reg aff berkeley heightshenney christopherberkeley heightshenney christopherberkeley heightswilliam collinsgeneral manager berkeley heightswillian collinsgeneral manager caryl kathi cordovaseattlel kathi cordovasvp of finance  treasurer seattlel kathi cordovasvp finance treasurer seattlestewart craigseattlestewart craigcoo  vice president seattlestewart craigcoo and vp seattlekeith crandellchicagokeith crandellchicagokeith crandell owner chicagokeith crandell owner chicagosuisse first boston credit owner new yorkrobert e currymenlo parkrobert e currydirector menlo parkspiegelman danielberkeley heightskenneth bryan dartgrand caymanuprichard davidberkeley heightsdeerfield capital lpnew yorkmanagement co ny deerfieldnew yorkdeerfield special situations fund international ltdroad town tortoladeerfield special situations fund lpnew yorkjean deleagedirector san franciscojean deleagedirector san franciscojean deleage san franciscoglenn dubinnew yorkeastern capital ltd owner grand caymanluke evninbostonjames e flynn owner new yorkmark frohlichseattlemark frohlichmedical director and vp seattlemark frohlichmedical director and vp seattleansbert gadickebostonnicholas galakatosbostonhradsky gregoryberkeley heightsgarrett gruenersan franciscohealthcare focus fund lp owner chicagohealthcare focus fund lp owner chicagodennis hennerbostonchristopher s henneydirector seattlechristopher s henneydirector berkeley heightschristopher s henneydirector seattlechristopher s henneydirector berkeley heightshighbridge capital corpgrand caymanhighbridge capital corpgrand cayman islandshighbridge capital management llcnew yorkhighbridge international llcgeorge town grand caymangregory t hradskydirector new yorkgregory t hradskydirector berkeley heightsgregory t hradskydirector berkeley heightsgregory t hradskydirector berkeley heightsrobert jacksonsvp  chief scientific offi short hillsbanham johnberkeley heightsbanham johnberkeley heightschiao judyberkeley heightsrobert l kirkmanseattlerobert l kirkmanchief business officer  vp seattlerobert l kirkmanchief business officer and vp seattlepeter langeckerdirector emeryvillepeter langeckerdirector emeryvillesteven lazarus owner chicagopierre legaultdirector berkeley heightssems lloydberkeley heightsmarxe austin w  greenhouse david m owner new yorkpaul mcbarronevp fin cfo  coo short hillspaul mcbarronevp finance  coo berkeley heightspaul mcbarronevp finance  coo berkeley heightspaul mcbarronevpfinancecfo  coo berkeley heightspaul mcbarronevpfinancecfo  coo berkeley heightspaul mcbarronevp finance cfo coo berkeley heightsjohn gordon mcviedirector short hillsjohn gordon mcviedirector berkeley heightsstanley morgan owner new yorkmpm asset management investors b llcbostonmpm bioventures ii gmbh  co parallel beteiligungs kgbostonmpm bioventures ii lpbostonmpm bioventures ii qp lpbostonrobert nelsendirector chicagorobert nelsenchicagorobert nelsendirector chicagorobert nelsendirector chicagobacopoulos nicholasberkeley heightsbacopoulos nicholasberkeley heightsguy p nohrasan franciscomcbarron paulberkeley heightsportfolio services ltdgrand caymangregory reyessenior vp research berkeley heightsspiro rombotispresident  ceo short hillsspiro george rombotispresident  ceo berkeley heightsspiro george rombotispresident  ceo berkeley heightsspiro george rombotispresident  ceo berkeley heightsspiro george rombotispresident  ceo berkeley heightslawrence a romelvp clinical operations seattlelloyd semsdirector san joselloyd semsdirector berkeley heightslloyd semsdirector berkeley heightslloyd semsdirector berkeley heightsrobert edward sosnowskiberkeley heightsrobert edward sosnowskivp marketing  sales berkeley heightsrobert edward sosnowskivp marketing  sales berkeley heightsdaniel k spiegelmandirector palo altodaniel k spiegelmandirector berkeley heightsrombotis spiroberkeley heightsmichael steinmetzbostonhenry swiecanew yorktang capital management llcsan diegotang capital partners lpsan diegokevin c tang owner david c upricharddirector carlsbaddavid c upricharddirector berkeley heightsdavid c upricharddirector berkeley heightsdavid c upricharddirector short hillsdavid c upricharddirector berkeley heightsstephen wertheimerdirector new yorkstephen wertheimerdirector new yorkrobert westwoodvp chem  preclin dev short hillsrobert westwoodvp chem  preclin dev berkeley heightskurt wheelerbostonrobert michael williamsfort collinsrobert michael williamsdirector fort collinsdr john francis womelsdorfvp business development short hillsdr john francis womelsdorfvp business development short hillsdr john francis womelsdorfvp business development berkeley heightsdr john francis womelsdorfvp business development berkeley heightsdr john francis womelsdorfvp business development berkeley heightspersons related to christopher s henney  anthera pharmaceuticals incnamepositioncityalain azanmenlo parkalain azanmenlo parkannette bianchidirector san brunoannette bianchisan brunoeric buatoismenlo parkklara dickinsonchief regulatory officer south san franciscobogdan dziurzynski haywardbogdan dziurzynskihaywardbogdan dziurzynskidirector haywardbogdan dziurzynskidirector haywardbogdan dziurzynski haywardsteven b engle san diegosteven b engleberkeleysteven b engle haywardursula fritschvp glob reg  compliance haywardbrent furseparsippanyjames healydirector menlo parkjames healy haywardjames healydirector haywardchristopher s henney seattlechristopher s henney haywardchristopher s henney haywardchristopher s henneydirector haywardcolin hislopchief medical officer haywardcolin hislopchief medical officer haywardcolin hislopchief medical officer haywardsamuel d isalynew yorksamuel d isalynew yorksamuel d isalynew yorksamuel d isalynew yorkgeorgina kilfoilsvp prod dev  project mngm haywardgeorgina kilfoilsvpproduct dev project mgmt haywardgeorgina kilfoilsvpproduct dev project mgmt haywardstephen lauvp corp  business dev haywarda rachel lehenydirector haywardmay liuprincipal accounting officer haywardchristopher p lowechief financial officer  cbo haywardchristopher p lowecfo and cbo haywardchristopher p lowecfo and cbo haywardchristopher p lowecfo and chief business officer haywardbrian mueller novatobrian muellerhaywardbrian mueller haywardbrian mueller haywarddebra odinkchief technology officer haywarddebra odinkchief technology officer haywarddebra odinkchief technology officer haywardcharles v olsonchief technology officer haywardorbimed advisors llcdirector new yorkorbimed advisors llcdirector new yorkorbimed advisors llc owner new yorkorbimed advisors llcdirector new yorkorbimed capital gp iv llcnew yorkorbimed capital gp iv llcnew yorkorbimed capital gp iv llcnew yorkjames penningtonhaywardjames e penningtonhaywardmichael powellmenlo parkphilip sager haywardphilip sager haywardphilip sager haywardalan e salzmansan brunoalan e salzmansan brunodonald j santeldirector haywardwilliam r shanahan jrchief medical officer san diegosofinnova management vi llcsan franciscosofinnova management vi llc owner san franciscosofinnova management vi llcmenlo parksofinnova venture affiliates vi lpmenlo parksofinnova venture partners vi gmbh  co kgmenlo parksofinnova venture partners vi l p owner san franciscosofinnova venture partners vi l p owner menlo parkdaniel k spiegelman haywarddaniel k spiegelman haywarddaniel k spiegelmandirector haywarddavid e thompsondirector haywarddavid e thompson haywarddavid e thompson haywardjohn craig thompsonpresident  ceo san diegopeter a thompsondirector haywardjoaquim triassr vp preclinical developmen haywardpaul f truexexecutive chaiman haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardpaul f truexpresident and ceo haywardvantagepoint venture associates iv llc owner san brunovantagepoint venture associates iv llc owner san brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv principals fund lpsan brunovantagepoint venture partners iv q lpsan brunovantagepoint venture partners iv q lpsan brunozenyaku kogyo co ltdtokyosanford s zweifach haywardsanford s zweifach haywardsanford s zweifach haywardpersons related to christopher s henney  cascadian therapeutics incnamepositioncityacm capital partners llcsan franciscoayer capital management lp owner san franciscoayer capital partners llcsan franciscoayer capital partners llcsan franciscorobert azelbydirector seattlepeter j barrisbaltimorebiotechnology value fund ii lpbiotechnology value fund ii lpchicagobiotechnology value fund ii lpchicagobiotechnology value fund ii lpsan franciscobiotechnology value fund l pbiotechnology value fund l pchicagobiotechnology value fund l pchicagobiotechnology value fund l psan franciscobiotechnology value trading fund os lpgrand caymans robert blairdirector bellevuestephen burleysan diegobvf incilbvf incilchicagobvf incilsan franciscobvf incilchicagobvf partners l pilbvf partners l pil owner chicagobvf partners l pil owner san franciscobvf partners l pilchicagobvf partners os ltdgrand caymangary christiansonchief operating officer bellevuegary christiansonchief operating officer seattlegary christiansonchief operating officer seattlehenney christopherseattlehenney christopherseattlespiegelman danielseattlespiegelman danielseattlehausman dianaseattlewilliams douglasseattlejulia marie eastlandcfo  vp corp dev seattlejulia marie eastlandcfo  vp corp development seattlejulia marie eastlandcfo  vp corp dev seattlegwen a fyfedirector sunnyvalechristianson garyseattlechristianson garyseattlegrowth equity opportunities iv llctimoniumdiana hausmanchief medical officer seattlediane hausmanseattlechristopher s henneydirector seattlechristopher s henneydirector seattlechristopher s henneydirector san diegochristopher s henneydirector seattleinvestment  llcchicagorichard l jacksondirector bellevuerichard l jacksondirector cincinnatirichard l jacksondirector seattlerichard l jacksondirector seattlesteven p jamesdirector venkatesan jayseattleeastland juliaseattleeastland juliaseattleshashi karanseattleshashi k karancorporate controller seattlerobert l kirkmanpresident  ceo seattlerobert l kirkmanpresidentceo bellevuerobert l kirkmanseattlerobert l kirkmanpresident  ceo seattlelynn kirkpatrickchief scientific officer tucsonmark n lampertdirector san franciscomark n lampertsan franciscomark n lampertsan franciscomark n lampertsan franciscoted w lovedirector sunnyvaleted w lovedirector seattlejoshua makowerdavid m mottgaithersburgscott dunseth myerspresident and ceo hackensacknea  gp llctimoniumnea partners  lptimoniumnew enterprise associates  lptimoniumscott robert petersonchief scientific officer seattlescott robert petersonchief scientific officer seattlejackson richardseattlejackson richardseattlekirkman robertseattlekirkman robertseattlejon sakodatimoniumscott d sandellbaltimorepeterson scottseattlekaran shashiseattlepeter w sonsinimenlo parkdaniel k spiegelmandirector palo altodaniel k spiegelmandirector seattledaniel k spiegelmandirector seattledaniel k spiegelmanpalo altodaniel k spiegelmandirector palo altodaniel k spiegelmandirector seattledaniel k spiegelmandirector seattlew vickery stoughtondirector bellevuew vickery stoughtondirector wellesley hillsw vickery stoughtondirector seattlew vickery stoughtondirector seattleedward a taylorcfo vp fin admin sec edmontonedward a taylorcfo vp fin  admin sec edmontonlove tedseattlejay venkatesansan franciscojay venkatesansan franciscojay venkatesansan franciscojay venkatesanevp and general manager seattlejay venkatesanevp and general manager seattleravi viswanathantimoniumstoughton wseattlestoughton wseattleluke nathaniel walkerseattlemichael c welshbellevuedouglas e williamsdirector seattledouglas e williamsdirector seattlepersons related to christopher s henney  prothena corp plcnamepositioncityrichard t collierdirector south san franciscoshane cookedirector dublin  irelandshane cookedirector south san franciscolars ekmandirector brisbanelars ekmandirector south san franciscoelan corp plcdublin elan corp plcdublin elan science one ltddublinjohn randall fawcettcontroller south san franciscokarl anders olof harfstranddirector south san franciscochristopher s henneydirector seattlechristopher s henneydirector south san franciscoarthur w homanchief legal officer palo altoarthur w homanchief legal officer south san franciscoarthur w homanchief legal officer south san franciscocarol d karpchief regulatory officer south san franciscogene g kinneypresident and ceo south san franciscomartin kollerchief medical officer south san franciscodavid b mcninchchief commercial officer south san franciscotran nguyenchief financial officer la jollatran nguyenchief financial officer south san franciscotara nickersonchief business officer south san franciscosarah b noonbergchief medical officer south san franciscoco plc perrigo owner dublin co plc perrigodublin dale b schenkpresident and ceo south san franciscodale b schenksouth san franciscodennis j selkoedirector south san franciscokarin l walkersee remarks palo altokarin l walkersee remarks south san franciscokarin l walkersee remarks south san franciscokarin l walkersee remarks south san franciscowagner m zagochief scientific officer south san francisco christopher s henney phd dsc – prothena you are here home  about  board of directors  christopher s henney phd dsc christopher s henney phd dscdirector christopher s henney phd dsc is chairman of the board of cascadian therapeutics inc formerly oncothyreon inc a biotechnology company where he also served as interim president and chief executive officer for part of   he is also vicechairman of the board of cyclacel pharmaceuticals inc and a member of the board of anthera pharmaceuticals inc from  to  dr henney served as chairman of the board and chief executive officer of dendreon corporation a biotechnology company that he cofounded he also cofounded and served as a director and in executive positions at both immunex corporation and icos corporation dr henney was also a director of mymetics corporation during  he is a  inductee to the biotechnology hall of fame dr henney earned his bsc in medical biochemistry his phd in experimental pathology and his dsc for contributions to the field of immunology from the university of birmingham england he has served on our board since  menuabout us management board of directors partnering our history pipeline neod prx prx prx publications investors press releases events  presentations financials  filings sec filings quarterly results key ratios irish statutory financial statements corporate governance committee composition stock information historic stock lookup investment calculator analyst coverage patients amyloidosis parkinson’s disease inflammatory disease  psoriasis  psoriatic arthritis clinical trials compassionate use careers core values compensation and benefits opportunities contact us headquarters prothena corporation plc adelphi plaza upper george’s street dún laoghaire co dublin a t ireland information tel     fax     email infoprothenacom anders o härfstrand md phd dennis j selkoe md scroll to top